Brief: Nurix Announces FDA Clearance Of Ind Application For Gs-6791/Nx-0479
17/04/2025 12:04
April 17 (Reuters) - Nurix Therapeutics Inc NRIX.O: NURIX ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR GS-6791/NX-0479 - A NOVEL IRAK4 DEGRADER FOR INFLAMMATORY CONDITIONS NURIX THERAPEUTICS INC - GILEAD TO BEGIN PHASE 1 STUDY IN Q2 2025 NURIX THERAPEUTICS INC - TO RECEIVE $5 MILLION MILESTONE PAYMENT FROM GILEAD NURIX THERAPEUTICS INC - ELIGIBLE FOR $420 MILLION IN FUTURE MILESTONES Source text: ID:nGNX9p7cxX Further company coverage: NRIX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nurix Therapeutics
See all newsNurix Therapeutics Q3 swings to profit on Roche collaboration
Brief: Nurix Extends Gilead Collaboration For Oncology Program
Commercialize Potential Best-In-Class Btk Degrader Bexobrutideg Across Malignant Hematology, Immunology And Neurology
Nurix Therapeutics Q2 revenue falls sharply, net loss widens; strikes up to $2.3 bln collab with Roche
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis